Kalorama Information Releases 2025 IVD Market Update: Innovation and Growth Surge in Clinical Chemistry, Immunoassays, and Molecular Diagnostics

News provided by

Jun 26, 2025, 09:53 ET

ARLINGTON, Va., June 26, 2025 /PRNewswire/ -- Kalorama Information, a leading authority on in vitro diagnostics (IVD) market intelligence, announces the release of its In Vitro Diagnostic (IVD) Trends and Market Update, 2025. Published in two volumes (April 2025 and Q4 2025), this twice-yearly update provides a timely, data-driven look at the dynamic IVD market, bridging the gap between Kalorama's annual flagship Worldwide Market for In Vitro Diagnostics report editions (18^th edition publishes September 2025).

For over 20 years, Kalorama Information has been a trusted source of healthcare market research, specializing exclusively in areas such as in vitro diagnostics (IVD), medical devices, sequencing, cell and gene therapy, and pharmaceuticals. Kalorama Information remains a global leader in healthcare market intelligence, known for high-quality research, innovative analysis, and trusted insights used by top industry decision-makers and media outlets alike.

Amid global economic shifts, declining COVID-19 revenues, and rising innovation in diagnostics, Kalorama's report offers vital insights for industry leaders navigating the changing IVD landscape. It covers core growth areas such as point-of-care (POC) diabetes testing, nucleic acid assays, gene testing, companion diagnostics, mass spectrometry, and HPV molecular diagnostics.

"From the perspective of conventional markets, revenues have rebounded and exceeded expectations in several areas," said Mary Anne Crandall, Senior Market Analyst at Kalorama Information and co-author of the report. "COVID-19 demand has plummeted over the last year, significantly impacting manufacturers' bottom lines. But we're seeing renewed growth in clinical chemistry, immunoassays, and molecular diagnostics—particularly in advanced technologies like nucleic acid assays and continuous glucose monitoring."

Key Takeaways from the Report:

POC Segment Grows Rapidly – Point-of-care diagnostics saw robust growth in Q4 2024.
Hematology Gains Traction – The hematology market rose by 6% in Q4 2024 compared to Q3.
High Growth in Molecular Segments – HPV molecular testing, NAAT screening, and nucleic acid assays posted double-digit year-over-year increases.
Market Momentum with Caveats – While most IVD sectors grew in 2024, Q4 saw slightly slower momentum than the previous quarter.

A Strategic Resource for Industry Stakeholders

This comprehensive report delivers:

A quarter-by-quarter analysis of key IVD product categories
New product developments in areas such as liquid biopsy, sequencing, and personalized medicine
Competitive performance metrics for leaders like Abbott, Roche, Siemens Healthineers, Thermo Fisher, QuidelOrtho, Danaher, and others
Exploration of emerging opportunities, including IVDR regulation, telemedicine, and laboratory staffing shortages

Audience & Strategic Applications

The report is built for:

IVD and medical device manufacturers
Diagnostics-focused investors and M&A teams
Clinical lab directors and scientific affairs leaders
Strategic planners, product managers, and regulatory affairs professionals

Stakeholders use the insights to:

Refine product development priorities
Adjust go-to-market and expansion strategies
Benchmark against competitors
Prepare for regulatory and reimbursement shifts

Availability

In Vitro Diagnostic (IVD) Trends and Market Update, 2025 is available for purchase now.

Buy the Report Here

About Kalorama Information

Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors.

Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD.

Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends.

With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis.

Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets.

For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website.

SOURCE Kalorama Information